These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 35979822)

  • 41. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
    Behringer A; Trappiel M; Berghausen EM; Ten Freyhaus H; Wellnhofer E; Odenthal M; Blaschke F; Er F; Gassanov N; Rosenkranz S; Baldus S; Kappert K; Caglayan E
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):369-79. PubMed ID: 26742933
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of FGFR Signaling With PD173074 Ameliorates Monocrotaline-induced Pulmonary Arterial Hypertension and Rescues BMPR-II Expression.
    Zheng Y; Ma H; Hu E; Huang Z; Cheng X; Xiong C
    J Cardiovasc Pharmacol; 2015 Nov; 66(5):504-14. PubMed ID: 26535780
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intermedin modulates hypoxic pulmonary vascular remodeling by inhibiting pulmonary artery smooth muscle cell proliferation.
    Mao SZ; Fan XF; Xue F; Chen R; Chen XY; Yuan GS; Hu LG; Liu SF; Gong YS
    Pulm Pharmacol Ther; 2014 Feb; 27(1):1-9. PubMed ID: 23796770
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regulatory effects of Prohibitin 1 on proliferation and apoptosis of pulmonary arterial smooth muscle cells in monocrotaline-induced PAH rats.
    Cao YY; Ba HX; Li Y; Tang SY; Luo ZQ; Li XH
    Life Sci; 2020 Jun; 250():117548. PubMed ID: 32173312
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum-glucocorticoid regulated kinase 1 regulates macrophage recruitment and activation contributing to monocrotaline-induced pulmonary arterial hypertension.
    Xi X; Liu S; Shi H; Yang M; Qi Y; Wang J; Du J
    Cardiovasc Toxicol; 2014 Dec; 14(4):368-78. PubMed ID: 24825325
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Thymoquinone attenuates monocrotaline-induced pulmonary artery hypertension via inhibiting pulmonary arterial remodeling in rats.
    Zhu N; Zhao X; Xiang Y; Ye S; Huang J; Hu W; Lv L; Zeng C
    Int J Cardiol; 2016 Oct; 221():587-96. PubMed ID: 27420584
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oxidized DNA Precursors Cleanup by NUDT1 Contributes to Vascular Remodeling in Pulmonary Arterial Hypertension.
    Vitry G; Paulin R; Grobs Y; Lampron MC; Shimauchi T; Lemay SE; Tremblay E; Habbout K; Awada C; Bourgeois A; Nadeau V; Paradis R; Breuils-Bonnet S; Roux-Dalvai F; Orcholski M; Potus F; Provencher S; Boucherat O; Bonnet S
    Am J Respir Crit Care Med; 2021 Mar; 203(5):614-627. PubMed ID: 33021405
    [No Abstract]   [Full Text] [Related]  

  • 48. [Pulmonary Vascular Remodeling Characteristics of Pulmonary Arterial Hypertension Mouse Model Induced by Left Pneumonectomy and Jugular Vein Injection of Monocrotaline Pyrrole].
    Gu L; Liu CJ; Xie L; Gu L; Yu L; Liu HM
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2022 Sep; 53(5):821-827. PubMed ID: 36224684
    [TBL] [Abstract][Full Text] [Related]  

  • 49. NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension.
    Mulvaney EP; Reid HM; Bialesova L; Bouchard A; Salvail D; Kinsella BT
    BMC Pulm Med; 2020 Apr; 20(1):85. PubMed ID: 32252727
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Icotinib Attenuates Monocrotaline-Induced Pulmonary Hypertension by Preventing Pulmonary Arterial Smooth Muscle Cell Dysfunction.
    Peng LY; Yu M; Yang MX; Liu P; Zhou H; Huang W; Kong H; Xie WP
    Am J Hypertens; 2020 Aug; 33(8):775-783. PubMed ID: 32301965
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prolonged inhaled NO attenuates hypoxic, but not monocrotaline-induced, pulmonary vascular remodeling in rats.
    Horstman DJ; Frank DU; Rich GF
    Anesth Analg; 1998 Jan; 86(1):74-81. PubMed ID: 9428855
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy.
    Schermuly RT; Pullamsetti SS; Kwapiszewska G; Dumitrascu R; Tian X; Weissmann N; Ghofrani HA; Kaulen C; Dunkern T; Schudt C; Voswinckel R; Zhou J; Samidurai A; Klepetko W; Paddenberg R; Kummer W; Seeger W; Grimminger F
    Circulation; 2007 May; 115(17):2331-9. PubMed ID: 17438150
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Silibinin efficacy in a rat model of pulmonary arterial hypertension using monocrotaline and chronic hypoxia.
    Zhang T; Kawaguchi N; Yoshihara K; Hayama E; Furutani Y; Kawaguchi K; Tanaka T; Nakanishi T
    Respir Res; 2019 Apr; 20(1):79. PubMed ID: 31023308
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dihydromyricetin prevents monocrotaline-induced pulmonary arterial hypertension in rats.
    Li Q; Wang J; Zhu X; Zeng Z; Wu X; Xu Y; Xie J; Yu J
    Biomed Pharmacother; 2017 Dec; 96():825-833. PubMed ID: 29078260
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension.
    Perros F; Ranchoux B; Izikki M; Bentebbal S; Happé C; Antigny F; Jourdon P; Dorfmüller P; Lecerf F; Fadel E; Simonneau G; Humbert M; Bogaard HJ; Eddahibi S
    J Am Coll Cardiol; 2015 Feb; 65(7):668-80. PubMed ID: 25677428
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of Shp2 ameliorates monocrotaline-induced pulmonary arterial hypertension in rats.
    Cheng Y; Yu M; Xu J; He M; Wang H; Kong H; Xie W
    BMC Pulm Med; 2018 Aug; 18(1):130. PubMed ID: 30086741
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Calcineurin/NFAT Signaling Modulates Pulmonary Artery Smooth Muscle Cell Proliferation, Migration and Apoptosis in Monocrotaline-Induced Pulmonary Arterial Hypertension Rats.
    He RL; Wu ZJ; Liu XR; Gui LX; Wang RX; Lin MJ
    Cell Physiol Biochem; 2018; 49(1):172-189. PubMed ID: 30134231
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vascular cell-specific roles of mineralocorticoid receptors in pulmonary hypertension.
    Menon DP; Qi G; Kim SK; Moss ME; Penumatsa KC; Warburton RR; Toksoz D; Wilson J; Hill NS; Jaffe IZ; Preston IR
    Pulm Circ; 2021; 11(3):20458940211025240. PubMed ID: 34211700
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension.
    Schermuly RT; Stasch JP; Pullamsetti SS; Middendorff R; Müller D; Schlüter KD; Dingendorf A; Hackemack S; Kolosionek E; Kaulen C; Dumitrascu R; Weissmann N; Mittendorf J; Klepetko W; Seeger W; Ghofrani HA; Grimminger F
    Eur Respir J; 2008 Oct; 32(4):881-91. PubMed ID: 18550612
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic effects of baicalin on monocrotaline-induced pulmonary arterial hypertension by inhibiting inflammatory response.
    Luan Y; Chao S; Ju ZY; Wang J; Xue X; Qi TG; Cheng GH; Kong F
    Int Immunopharmacol; 2015 May; 26(1):188-93. PubMed ID: 25601497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.